Arbutus Biopharma Corporation (ABUS)

[Ubertino]

Gilead ( GILD) Agrees to a Discounted Price of $46,000 for Sovaldi in Europe

2/13/2015 6:35:00 AM

(Reuters) - Drugmaker Gilead has agreed on a price for its hepatitis C drug Sovaldi of 41,000 euros ($46,625) for a 12-week treatment for Germany's statutory medical insurers, the GKV association of Germany's statutory medical insurers said.

GKV, who provides coverage for about nine out of 10 Germans, said the U.S. biotechnology company had agreed on a price of 43,562.52 euros, which is subject to a 5.88 percent discount for statutory insurers.

http://www.biospace.com/news_story.aspx?StoryID=364653&full=1